Dear Ms. Schafer:


This “Changes Being Effected” supplemental new drug application provides for a Geriatric Use subsection under the **PRECAUTIONS** section of the product package insert.

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the FPL submitted November 15, 2002.

If a future supplement is submitted, the following revisions should be made:

1. The pH and osmolality should be added to the **DESCRIPTION** section of the package insert.

2. The **HOW SUPPLIED** section of the package insert should include the target fill volume for each container size and the color and type of plastic for the bottle container, dropper tip, and cap. Cap color should be consistent with that assigned by the American Academy of Ophthalmology. The storage statement should be modified to read, “Store at 2°C – 25°C (36°F-77°F).

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

**MEDWATCH, HF-2**
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Raphael Rodriguez, Regulatory Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Wiley Chambers
6/23/03 11:30:45 AM